Neurology

Anavex Life Sciences has announced new 48-week results for its placebo-controlled, phase 2b/3 trial (NCT04314934) of blarcamesine, an investigational...

According to a new announcement, the FDA has granted fast track designation to Teva Pharmaceuticals’ emrusolmin, a small-molecule modulator of protein...

WATCH TIME: 4 minutes | Captions are auto-generated and may contain errors. "It’s exciting to see that, for the first time here in the United States,...

Centers for Disease Control and Prevention. Health Disparities. Healthy Youth (CDC, 2025); https://www.cdc.gov/healthyyouth/disparities/index.htm. Fei...

In recent years, interest in orexin receptor agonists has surged due to their potential to address the underlying cause of narcolepsy–orexin deficienc...

At the 2025 Alzheimer’s Association International Conference, held July 27-30, in Toronto, Canada, Alzheimer disease (AD) expert Sharon Cohen, MD, FRC...

New data from Rapport Therapeutics’ ongoing phase 2a RAP-219-FOS-201 trial (NCT06377930) revealed that RAP-219, an investigational TARPγ8-specific AMP...

Interim safety and tolerability results from the phase 3 Argus clinical trial (NCT04462770) showed that investigational EPX-100 (Harmony Biosciences)...

The FDA was busy in August 2025, making a number of decisions on potential new therapeutic agents, including granting approvals and issuing a complete...

A recently published phase 2 randomized, placebo-controlled trial demonstrated that three infusions of 10 × 10⁶ allogeneic human mesenchymal stem cell...